Concerns remain for ‘Viagra for women’ twice rejected by FDA

Jun 2, 2015, 7:00 AM

WASHINGTON (AP) — The makers of a pill intended to boost sexual desire in women will try again this week to persuade regulators that the drug warrants approval after two rejections.

But a new review released by the Food and Drug Administration shows government scientists still have concerns about whether the drug’s benefits outweigh its risks. The FDA review highlights several safety issues with flibanserin, including low blood pressure and fainting spells. Those problems increased when patients combined the drug with alcohol and some other medications, according to the document.

A panel of FDA experts will discuss the drug at a public meeting Thursday, before voting on whether to recommend its approval.

The ongoing saga of Sprout Pharmaceutical’s much-debated drug illustrates the complex politics and science surrounding women’s sexuality.

For decades, drugmakers have tried unsuccessfully to develop a female equivalent to Viagra, the blockbuster drug that treats men’s erectile dysfunction by increasing blood flow. But disorders of women’s sexual desire have proven resistant to drugs that act on blood flow, hormones and other simple biological functions.

Supporters of Sprout’s drug say women’s sexual disorders have been long overlooked by the FDA. But critics argue that drug development efforts like Sprout’s medicalize women’s sexual problems, which are often related to stress, relationship issues and other life circumstances.

“There are certainly women who have low libido and are distressed by it,” says Dr. Adriane Fugh-Berman, an associate professor at Georgetown University. “But for those women therapy is the best solution, because this is not a medical disease.”

Other critics say they would support a safe and effective drug for treating women’s libido problems, but none has yet emerged.

“If a company could show that a drug is effective based on clinically significant outcome measurements, then we’d be for it,” says Cindy Pearson, executive director of the National Women’s Health Network.

Flibanserin is the first drug to approach the issue through brain chemistry. Originally studied as an antidepressant, the pill was repurposed as a libido treatment after women in company studies reported higher levels of sexual satisfaction. But the FDA has twice rejected the drug because of lackluster effectiveness and side effects including fatigue, dizziness and nausea.

Clinicians who helped study flibanserin point out that they already prescribe other antidepressants without FDA approval to treat sexual desire disorders. They argue that those drugs, including Wellbutrin and Viibryd, carry worse side effects than flibanserin, such as agitation and seizures.

“We use them all the time for female sexual dysfunction,” says Dr. James Simon, a gynecologist who helped conduct several key studies of flibanserin. “The problem is that the side effect profile for doses that are effective for increasing desire and orgasm can be very high.”

Simon says the lack of an FDA-approved option for female sexual dysfunction means doctors must balance issues of safety and lack of insurance coverage while trying to help patients.

“We’re out there in the trenches every day trying to find a happy medium.”

It’s not entirely clear how flibanserin increases desire, but researchers point to its ability to boost dopamine — a brain chemical associated with appetite — while lowering serotonin, which is linked to feelings of satiation.

The FDA first rejected flibanserin in 2010 after a panel of expert advisers unanimously voted against the drug, saying its benefits did not outweigh its risks. Company studies showed women taking flibanserin reported roughly one more sexually satisfying experience per month than women taking placebo.

The drug’s initial developer, Boehringer Ingelheim, abandoned work on the drug in 2011 and sold it to Sprout, a startup company from Raleigh, North Carolina. Sprout resubmitted the drug with additional effectiveness and safety data, but the FDA again rejected the drug in October 2013. Sprout submitted the drug yet again earlier this year after filing a formal dispute over the FDA’s second rejection.

FDA’s review posted Tuesday underscores the ongoing rift between regulators and the company. The FDA acknowledges that flibanserin resulted in statistically significant increases in sexual events and desire, while decreasing distress. But the review concludes: “The fundamental question is whether these observed placebo-corrected treatment effects outweigh the risks associated with treatment.”

The FDA will ask its expert panel whether extra safety measures — including certification for doctors who wish to prescribe the drug — should be required if the drug is approved.

The FDA is not required to follow the advice of its panelists. The agency is expected to make a decision on whether to approve the drug in August..

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Business

FILE - In this April 4, 2017, file photo, fountains erupt along the Las Vegas Strip in Las Vegas. A...
Associated Press

Lawsuit: Vegas Strip resorts used vendor to fix hotel rates

LAS VEGAS (AP) — A federal lawsuit in Nevada is seeking class-action damages for countless hotel patrons who booked rooms in Las Vegas since 2019, alleging that most hotel-casinos on the Las Vegas Strip have used a third-party vendor to illegally fix prices. The complaint filed Wednesday in U.S. District Court in Las Vegas alleges […]
19 hours ago
Associated Press

Jury: $1M to Oregon woman told ‘I don’t serve Black people’

PORTLAND, Ore. (AP) — A jury has awarded an Oregon woman $1 million in damages after finding she was discriminated against by a gas station employee who told her, “I don’t serve Black people.” The Multnomah County jury’s award this week to Portland resident Rose Wakefield, 63, included punitive damages of $550,000. Wakefield’s lawyer, Gregory […]
19 hours ago
FILE - The Hasbro logo is seen on April 26, 2018, in New York. Toymaker Hasbro said Thursday, Jan. ...
Associated Press

Toymaker Hasbro laying off 1,000 to cut costs

PAWTUCKET, R.I. (AP) — Toymaker Hasbro said Thursday it is cutting about 1,000 jobs as part of moves announced last year to save up to $300 million annually by 2025. The nearly century-old Rhode Island-based company behind Monopoly, Play-Doh and My Little Pony toys said the layoffs amount to 15% of its global full-time workforce. […]
19 hours ago
Syringes with vaccines are prepared at the L.A. Care and Blue Shield of California Promise Health P...
Associated Press

FDA’s advisers back plan to simplify COVID-19 vaccinations

The U.S. is poised to make COVID-19 vaccinations more like a yearly flu shot, a major shift in strategy despite a long list of questions about how to best protect against a still rapidly mutating virus. The Food and Drug Administration asked its scientific advisers Thursday to help lay the groundwork for switching to once-a-year […]
19 hours ago
FILE - People walk on the sand near the shuttered San Onofre nuclear power plant in San Clemente, C...
Associated Press

US sweetens pot to study siting for spent nuke fuel storage

ALBUQUERQUE, N.M. (AP) — The U.S. government has long struggled to find a permanent solution for storing or disposing of spent nuclear fuel from commercial nuclear power plants, and opposition to such a site is flaring up again as New Mexico lawmakers debate banning a facility without state consent. The state’s prospective ban cleared its […]
19 hours ago
FILE - This Aug. 11, 2019, photo shows a Visa logo on a credit card in New Orleans. Visa Inc. repor...
Associated Press

Visa 1Q profits rise 6%, new CEO to take over Feb. 1

NEW YORK (AP) — Payment processing giant Visa Inc. said Thursday that its profits rose 6% in its latest quarter from a year earlier, helped by the continued rise of digital payments across the globe. The company also said its current CEO, Al Kelly, will step down on Wednesday. He will be replaced by his […]
19 hours ago

Sponsored Articles

...
Fiesta Bowl Foundation

Celebrate 50 years of Vrbo Fiesta Bowl Parade magic!

Since its first production in the early 1970s, the Vrbo Fiesta Bowl Parade presented by Lerner & Rowe has been a staple of Valley traditions, bringing family fun and excitement to downtown Phoenix.
(Photo via MLB's Arizona Fall League / Twitter)...
Arizona Fall League

Top prospects to watch at this year’s Arizona Fall League

One of the most exciting elements of the MLB offseason is the Arizona Fall League, which began its 30th season Monday.
...
Children’s Cancer Network

Children’s Cancer Network celebrates cancer-fighting superheroes, raises funds during September’s Childhood Cancer Awareness Month

Jace Hyduchak was like most other kids in his kindergarten class: He loved to play basketball, dress up like his favorite superheroes and jump as high as his pint-sized body would take him on his backyard trampoline.
Concerns remain for ‘Viagra for women’ twice rejected by FDA